Curaleaf Holdings (CURLF) Amortization of Deferred Charges (2019 - 2024)
Curaleaf Holdings (CURLF) recorded quarterly Amortization of Deferred Charges of $2.8 million in Q4 2024, down 18.89% quarter-over-quarter from $3.4 million in Q3 2024, and up 206.63% on a YoY basis from $897512.3 in Q1 2024.
Curaleaf Holdings (CURLF) Amortization of Deferred Charges (2019 - 2024) Analysis & Trends
Curaleaf Holdings' Amortization of Deferred Charges history runs 6 years deep, the most recent figure standing at $2.8 million for Q4 2024.
- In Q4 2024, Amortization of Deferred Charges rose 206.63% year-over-year to $2.8 million; the TTM figure through Dec 2024 stood at $9.8 million (up 194.41% YoY), while the FY2025 annual figure was $9.1 million, down 35.57% from the prior year.
- Amortization of Deferred Charges was $2.8 million for Q4 2024 at Curaleaf Holdings, down from $3.4 million in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $13.4 million in Q3 2021 to a low of -$25.9 million in Q4 2021.
- Historically, Amortization of Deferred Charges has averaged $2.2 million across 5 years, with a median of $4.4 million in 2022.
- Biggest YoY gain for Amortization of Deferred Charges was 4116.16% in 2021; the steepest drop was 1400.75% in 2021.
- A 5-year view of Amortization of Deferred Charges shows it stood at $2.0 million in 2020, then plunged by 1400.75% to -$25.9 million in 2021, then jumped by 120.66% to $5.3 million in 2022, then tumbled by 148.28% to -$2.6 million in 2023, then soared by 206.63% to $2.8 million in 2024.
- The last three Amortization of Deferred Charges figures came in at $2.8 million (Q4 2024), $3.4 million (Q3 2024), and -$2.6 million (Q4 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Curaleaf Holdings | - | - | 157.29 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 2.75 Mn |
| Dec 31, 2024 | 2.75 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Sep 30, 2024 | 3.39 Mn |
| Dec 31, 2023 | -2.58 Mn |
| Dec 31, 2023 | -2.58 Mn |
| Sep 30, 2023 | 6.23 Mn |
| Sep 30, 2023 | 6.23 Mn |
| Dec 31, 2022 | 5.35 Mn |
| Dec 31, 2022 | 5.35 Mn |
| Sep 30, 2022 | -19.37 Mn |
| Sep 30, 2022 | -19.37 Mn |
| Jun 30, 2022 | 13.12 Mn |
| Jun 30, 2022 | 13.12 Mn |
| Mar 31, 2022 | 12.51 Mn |
| Mar 31, 2022 | 12.51 Mn |
| Dec 31, 2021 | -25.87 Mn |
| Dec 31, 2021 | -25.87 Mn |
| Sep 30, 2021 | 13.40 Mn |
| Sep 30, 2021 | 13.40 Mn |